Latus Bio closed a $97 million Series A to fund its AAV capsid-variant platform, with initial clinical work expected to start across Huntington’s disease (LTS-201) and late-infantile neuronal ceroid lipofuscinosis type 2 (LTS-101). The financing is structured to carry operations through key milestones tied to early clinical data. The company’s focus on capsid variants aims to differentiate by enabling more efficient delivery, potentially addressing limitations that have constrained wider application of AAV gene therapies. Near-term expectations center on when each program produces initial human proof-of-concept data.